Dicerna Pharmaceuticals
2 known investors
A pharmaceutical company developing treatments for serious chronic diseases with a focus on long-term health solutions and improving medicine access and affordability globally. The company conducts research and development, collaborates with scientists and biotech innovators, and has reached millions of patients through its innovative therapeutic approaches.
Investors Β· 2
Non-dilutive funding Β· 4 SBIR/STTR awards
Federal grants β no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $184.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts β non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Dicerna Pharmaceuticals do?
- A pharmaceutical company developing treatments for serious chronic diseases with a focus on long-term health solutions and improving medicine access and affordability globally. The company conducts research and development, collaborates with scientists and biotech innovators, and has reached millions of patients through its innovative therapeutic approaches.
- Who are Dicerna Pharmaceuticals's investors?
- Dicerna Pharmaceuticals's investors include Access Biotechnology, Bain Capital Life Sciences.